Divyani Chowdhury, Nivedita Sarkar, Pasupuleti H H M Sai Hanuman, Avinaba Sinha, Sudipta Pati, Sanjoy Chatterjee, Prateek V Jain, Pattatheyil Arun, Paromita Roy, Indu Arun, Indranil Mallick
{"title":"涎腺管癌手术及辅助放疗的疗效分析。","authors":"Divyani Chowdhury, Nivedita Sarkar, Pasupuleti H H M Sai Hanuman, Avinaba Sinha, Sudipta Pati, Sanjoy Chatterjee, Prateek V Jain, Pattatheyil Arun, Paromita Roy, Indu Arun, Indranil Mallick","doi":"10.4103/jcrt.jcrt_1842_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Salivary duct carcinoma (SDC) forms an uncommon and aggressive subtype of salivary gland neoplasms with early recurrences and metastases. Their treatment includes surgery and adjuvant radiotherapy. They overexpress androgen receptors (AR) and human epidermal receptor 2 (HER2), similar to breast carcinomas. There is limited data on SDCs treated with curative intent from Asia.</p><p><strong>Objective: </strong>In this retrospective analysis, we reviewed SDCs treated between 2012 and 2022. The aim of this study was to study the outcome of SDCs in patients who were treated with curative intent. The primary objectives of the study were to study the overall survival (OS) and disease-free survival (DFS) in patients of salivary duct cancer treated with curative intent, compare OS and DFS among various groups, and identify certain critical clinical or pathological attributes that may affect disease outcomes.</p><p><strong>Materials and methods: </strong>Patient demographics, tumor characteristics, treatment details, and outcomes were recorded for 48 patients in REDCap (electronic data collection system) and all eligible patients were contacted for survival status.</p><p><strong>Statistical analysis: </strong>Statistical analysis was done using SPSS software and survival analysis using the log-rank test and Cox regression.</p><p><strong>Results: </strong>After a median follow-up of 13.8 months ranging from 0.5 to 125.2 months, median DFS and OS were 11.4 and 13.8 months. Node (s) positive patients showed numerically inferior DFS, 66.6% vs. 81.7% at one year and 22.8% vs. 67.4% at two years (P = 0.061) with a hazard ratio (HR) 2.23 (95% confidence interval [CI]: 0.94-5.29, P = 0.068) and inferior OS, 91.7% vs. 100% at one year and 72.2% vs. 86.7% at two years (P = 0.068) with HR 3.41 (95% CI: 0.84-13.79, P = 0.085). Patients with extranodal extension had numerically inferior DFS, 59.1% vs. 85.9% (P = 0.119) with HR 1.96 (95% CI of 0.82-4.68, P = 0.126) and lower OS, 90.9% vs. 100% (P = 0.112) at one year with HR 2.96 (95% CI of 0.72-12.02, P = 0.129). Despite the large numerical difference, the P value was not statistically significant due to limited sample size.</p><p><strong>Conclusion: </strong>Salivary duct cancers, even when treated curatively, have early and distant failures. Over-expression of HER2-neu and AR provide an opportunity to improve the outcomes of curative intent treatment for this cancer with targeted agents and robust data is required to investigate the role of adjuvant endocrine or HER-2 targeted therapies.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"670-677"},"PeriodicalIF":1.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of curative surgery and adjuvant radiation therapy in salivary duct carcinoma.\",\"authors\":\"Divyani Chowdhury, Nivedita Sarkar, Pasupuleti H H M Sai Hanuman, Avinaba Sinha, Sudipta Pati, Sanjoy Chatterjee, Prateek V Jain, Pattatheyil Arun, Paromita Roy, Indu Arun, Indranil Mallick\",\"doi\":\"10.4103/jcrt.jcrt_1842_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Salivary duct carcinoma (SDC) forms an uncommon and aggressive subtype of salivary gland neoplasms with early recurrences and metastases. Their treatment includes surgery and adjuvant radiotherapy. They overexpress androgen receptors (AR) and human epidermal receptor 2 (HER2), similar to breast carcinomas. There is limited data on SDCs treated with curative intent from Asia.</p><p><strong>Objective: </strong>In this retrospective analysis, we reviewed SDCs treated between 2012 and 2022. The aim of this study was to study the outcome of SDCs in patients who were treated with curative intent. The primary objectives of the study were to study the overall survival (OS) and disease-free survival (DFS) in patients of salivary duct cancer treated with curative intent, compare OS and DFS among various groups, and identify certain critical clinical or pathological attributes that may affect disease outcomes.</p><p><strong>Materials and methods: </strong>Patient demographics, tumor characteristics, treatment details, and outcomes were recorded for 48 patients in REDCap (electronic data collection system) and all eligible patients were contacted for survival status.</p><p><strong>Statistical analysis: </strong>Statistical analysis was done using SPSS software and survival analysis using the log-rank test and Cox regression.</p><p><strong>Results: </strong>After a median follow-up of 13.8 months ranging from 0.5 to 125.2 months, median DFS and OS were 11.4 and 13.8 months. Node (s) positive patients showed numerically inferior DFS, 66.6% vs. 81.7% at one year and 22.8% vs. 67.4% at two years (P = 0.061) with a hazard ratio (HR) 2.23 (95% confidence interval [CI]: 0.94-5.29, P = 0.068) and inferior OS, 91.7% vs. 100% at one year and 72.2% vs. 86.7% at two years (P = 0.068) with HR 3.41 (95% CI: 0.84-13.79, P = 0.085). Patients with extranodal extension had numerically inferior DFS, 59.1% vs. 85.9% (P = 0.119) with HR 1.96 (95% CI of 0.82-4.68, P = 0.126) and lower OS, 90.9% vs. 100% (P = 0.112) at one year with HR 2.96 (95% CI of 0.72-12.02, P = 0.129). Despite the large numerical difference, the P value was not statistically significant due to limited sample size.</p><p><strong>Conclusion: </strong>Salivary duct cancers, even when treated curatively, have early and distant failures. Over-expression of HER2-neu and AR provide an opportunity to improve the outcomes of curative intent treatment for this cancer with targeted agents and robust data is required to investigate the role of adjuvant endocrine or HER-2 targeted therapies.</p>\",\"PeriodicalId\":94070,\"journal\":{\"name\":\"Journal of cancer research and therapeutics\",\"volume\":\"21 3\",\"pages\":\"670-677\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer research and therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jcrt.jcrt_1842_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcrt.jcrt_1842_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Outcomes of curative surgery and adjuvant radiation therapy in salivary duct carcinoma.
Introduction: Salivary duct carcinoma (SDC) forms an uncommon and aggressive subtype of salivary gland neoplasms with early recurrences and metastases. Their treatment includes surgery and adjuvant radiotherapy. They overexpress androgen receptors (AR) and human epidermal receptor 2 (HER2), similar to breast carcinomas. There is limited data on SDCs treated with curative intent from Asia.
Objective: In this retrospective analysis, we reviewed SDCs treated between 2012 and 2022. The aim of this study was to study the outcome of SDCs in patients who were treated with curative intent. The primary objectives of the study were to study the overall survival (OS) and disease-free survival (DFS) in patients of salivary duct cancer treated with curative intent, compare OS and DFS among various groups, and identify certain critical clinical or pathological attributes that may affect disease outcomes.
Materials and methods: Patient demographics, tumor characteristics, treatment details, and outcomes were recorded for 48 patients in REDCap (electronic data collection system) and all eligible patients were contacted for survival status.
Statistical analysis: Statistical analysis was done using SPSS software and survival analysis using the log-rank test and Cox regression.
Results: After a median follow-up of 13.8 months ranging from 0.5 to 125.2 months, median DFS and OS were 11.4 and 13.8 months. Node (s) positive patients showed numerically inferior DFS, 66.6% vs. 81.7% at one year and 22.8% vs. 67.4% at two years (P = 0.061) with a hazard ratio (HR) 2.23 (95% confidence interval [CI]: 0.94-5.29, P = 0.068) and inferior OS, 91.7% vs. 100% at one year and 72.2% vs. 86.7% at two years (P = 0.068) with HR 3.41 (95% CI: 0.84-13.79, P = 0.085). Patients with extranodal extension had numerically inferior DFS, 59.1% vs. 85.9% (P = 0.119) with HR 1.96 (95% CI of 0.82-4.68, P = 0.126) and lower OS, 90.9% vs. 100% (P = 0.112) at one year with HR 2.96 (95% CI of 0.72-12.02, P = 0.129). Despite the large numerical difference, the P value was not statistically significant due to limited sample size.
Conclusion: Salivary duct cancers, even when treated curatively, have early and distant failures. Over-expression of HER2-neu and AR provide an opportunity to improve the outcomes of curative intent treatment for this cancer with targeted agents and robust data is required to investigate the role of adjuvant endocrine or HER-2 targeted therapies.